- Home
- IMA vs YI Comparison
IMA vs YI Comparison
Compare IMA & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMA | YI |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | China |
| Employees | 15 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 57.1M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | IMA | YI |
|---|---|---|
| Price | $6.04 | $5.56 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 369.6K | 9.8K |
| Earning Date | 05-15-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.94 | $2.48 |
| 52 Week High | $17.50 | $11.17 |
Technical Indicators
Market Signals| Indicator | IMA | YI |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 33.74 |
| Support Level | $5.52 | $5.35 |
| Resistance Level | $7.17 | $7.18 |
| Average True Range (ATR) | 0.36 | 0.42 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 77.12 | 22.78 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.